Hemogenyx Pharmaceuticals (LON:HEMO) Trading Down 2.5% – What’s Next?

Hemogenyx Pharmaceuticals Plc (LON:HEMO)’s stock price traded down 2.5% during mid-day trading on Tuesday . The stock traded as low as GBX 390 ($4.82) and last traded at GBX 395 ($4.88). 2,561 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 11,130 shares. The stock had previously closed at GBX 405 ($5.01).

Hemogenyx Pharmaceuticals Trading Up 3.2 %

The company has a market capitalization of £5.36 billion, a PE ratio of -40,000.00 and a beta of 3.14. The company has a fifty day simple moving average of GBX 146 and a 200-day simple moving average of GBX 51.93. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 92.09.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.